Header Logo

Connection

MEGHANA TRIVEDI to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Breast Neoplasms.
MEGHANA TRIVEDI
Connection Strength
4.318
Breast Neoplasms
  1. Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic. Int J Clin Pharm. 2023 Dec; 45(6):1396-1404.
    View in: PubMed
    Score: 0.369
  2. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics. 2023 06; 41(6):709-718.
    View in: PubMed
    Score: 0.362
  3. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
    View in: PubMed
    Score: 0.335
  4. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
    View in: PubMed
    Score: 0.299
  5. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
    View in: PubMed
    Score: 0.274
  6. Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 06; 53(6):612-620.
    View in: PubMed
    Score: 0.270
  7. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
    View in: PubMed
    Score: 0.256
  8. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
    View in: PubMed
    Score: 0.254
  9. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct; 153(3):591-7.
    View in: PubMed
    Score: 0.215
  10. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.205
  11. The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol. 2014; 131(3):133-40.
    View in: PubMed
    Score: 0.189
  12. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501.
    View in: PubMed
    Score: 0.168
  13. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011 Oct; 20 Suppl 3:S42-9.
    View in: PubMed
    Score: 0.163
  14. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
    View in: PubMed
    Score: 0.087
  15. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719.
    View in: PubMed
    Score: 0.080
  16. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020 Jul; 182(2):401-409.
    View in: PubMed
    Score: 0.075
  17. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
    View in: PubMed
    Score: 0.071
  18. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.067
  19. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. Ann Pharmacother. 2019 05; 53(5):501-509.
    View in: PubMed
    Score: 0.067
  20. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
    View in: PubMed
    Score: 0.067
  21. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
    View in: PubMed
    Score: 0.058
  22. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016 06; 157(2):203-210.
    View in: PubMed
    Score: 0.056
  23. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.056
  24. The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
    View in: PubMed
    Score: 0.053
  25. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.053
  26. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97.
    View in: PubMed
    Score: 0.048
  27. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
    View in: PubMed
    Score: 0.046
  28. Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Res. 2012 May 23; 14(3):310.
    View in: PubMed
    Score: 0.043
  29. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.